Navigation Links
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Date:5/30/2009

primarily target tissue clusterin levels with serum levels as an indicator of biological effect. - Higher incidence of stable disease (20 patients in OGX-011 plus docetaxel arm versus 12 patients in docetaxel arm) with lower incidence of disease progression as best response (1 patient in OGX- 011 plus docetaxel arm versus 4 patients in docetaxel arm) occurred in patients with measurable disease who were treated with OGX-011 plus docetaxel compared to the docetaxel arm; although, the incidence of overall response was comparable.

OGX-011 treatment was well tolerated in combination with docetaxel. There was an increase in incidence of mild fever, chills and creatinine levels (a laboratory measure for reduced kidney function) and a moderate to significant decrease in circulating lymphocytes in the blood (another laboratory measure) without any increase in infection rate compared to the docetaxel arm. The investigators concluded that the combination was well tolerated.

Brent Blumenstein, an independent statistician who conducted additional sensitivity analyses of the results, found that the survival benefit in the OGX-011 arm to be robust and not dependent on clinical trial sites or baseline characteristics of the patients.

"There is a clear separation of the survival curves," said Blumenstein. "A hazard ratio of 0.61 indicates a distinct difference in survival rates and fully justifies further Phase 3 trials. It is rare for a new intervention at this stage of development to have such strong data from a randomized clinical trial."

Cormack added, "These data clearly justify advancing to Phase 3 development, and we expect these data will be key in our partnering discussions for future clinical development and potential commercialization."

The trial was supported by funding from the Canadian Cancer Society and was conducted by the NCIC Clinical Trials
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
3. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
4. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
7. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
9. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Research ... California Los Angeles, Boston University School of Medicine, Frederick National Laboratory for Cancer ... the world’s first multidisciplinary Open Access journal. , Christopher Ryan PhD, of ...
(Date:8/31/2015)... ... August 31, 2015 , ... The ... supply chain risk management and resiliency practitioners with luminaries and thought leaders to ... and be recognized for their innovations and performance excellence. At that time its ...
(Date:8/31/2015)... Aug. 31, 2015 MabVax Therapeutics Holdings, Inc. ... that the Company,s lead antibody, HuMab 5B1, will be ... presentations during the upcoming World Molecular Imaging Congress (WMIC) ... 2-5, 2015. Researchers from the Department of Radiology at ... on the use of MabVax,s lead antibody as a ...
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Israel Biomedical Sensors Market - Growth, Trends & Forecasts ... The Israel Biomedical Sensors market is estimated at $0.19 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology Technology:Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2
... movies of living cell membranes, taken by a research ... New Mexico, have clarified a decades-old enigma surrounding receptor ... of the Journal of Cell Biology , promise ... development. The work focuses on G protein-coupled receptors ...
... Feb. 7, 2011 Gizmox, the developer of ... their entrance into the Business Mobility Market. Visual WebGui,s ... applications to the Web or Cloud, has now been ... using a simple mapping and configuration tool.  IdeoMobile, in ...
... 2011 Cmed Technology ... host a roundtable and give a presentation about electronic ... Summit for Clinical Ops Executives ( SCOPE ) conference ... (Logo: http://photos.prnewswire.com/prnh/20100707/NY31446LOGO) As part of SCOPE,s two-day ...
Cached Biology Technology:Expanding drug development horizons: Receptor behaviors observed in living cell membranes 2Gizmox Enters the Business Mobile Application Market - Visual WebGui Based Solutions Deployed in Major Financial and Medical Institutions 2Gizmox Enters the Business Mobile Application Market - Visual WebGui Based Solutions Deployed in Major Financial and Medical Institutions 3Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 2Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 3
(Date:8/12/2015)... SPRINGS, Florida , August 12, 2015 ... the pace of mobile payment innovation and advanced biometrics ... to replace the way consumers rely on using their ... ahead with reinventing the future for payment services led ... (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... follows form" might have been written to describe proteins, ... nature,s workhorse biomolecules enables each to carry out its ... X-ray protein crystallography, in which a beam of x-rays ... protein,s atoms, creating a diffraction pattern of dots that ...
... prescribed drugs for the treatment of heart failure are beta-blockers ... the heart,s workload. The drugs were thought to produce those ... study led by scientists at Temple University School of Medicine, ... counteracting the effects of an enzyme known as GRK2. The ...
... Nov. 5, 2013  The AVS has selected its major award ... to encourage excellence in research and innovation in technical areas ... award winners: Medard W. Welch Award— Dr. ... Barbara, "For seminal contributions to the theory of heterojunctions and ...
Cached Biology News:Bringing out the best in X-ray crystallography data 2Temple researchers uncover clues to how existing heart drugs work 2AVS Announces Its Major Award Winners of 2013 2AVS Announces Its Major Award Winners of 2013 3AVS Announces Its Major Award Winners of 2013 4AVS Announces Its Major Award Winners of 2013 5AVS Announces Its Major Award Winners of 2013 6
... Antibody to Cytokeratin 5 / 6 ... molecular weight, basic type of cytokeratin expressed ... cell layers of stratified epithelia as well ... mesothelial cells and mesothelioma. Cytokeratin 6 (56 ...
Aldolase A (N-15)...
... Y2 Receptor antiserum This NPY Y2 ... level and is currently being characerized in brain. ... and mouse and appears to work better on ... rat. For full characterizarion in dorsal root ganglion ...
Black Polypropylene 384 Round Well Plate 70/Box...
Biology Products: